Clear Cell Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLR003 MIFTS: 56	Clear Cell Adenocarcinoma Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Clear Cell Adenocarcinoma

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma ¹² ¹⁵

Mesonephroma ¹² ⁴⁴ ⁷³

Water-Clear Cell Adenocarcinoma ¹² ⁷³

Adenocarcinoma, Clear Cell ⁴⁴ ⁷³

Mesonephroid Clear Cell Carcinoma ¹²

Water-Clear Cell Carcinoma ¹²

Adenocarcinoma Clear Cell ⁵⁵

Mesonephroma, Malignant ¹²

Malignant Mesonephroma ¹²

Wolffian Duct Neoplasm ¹²

Mesonephric Tumor ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4468

MeSH ⁴⁴ D008649 D018262

NCIt ⁵⁰ C36815 C3766 C4072 more

SNOMED-CT ⁶⁸ 189633003 189861007 2221008 more

UMLS ⁷³ C0025490 C0206681 C0334322 more

Sources

Summaries for Clear Cell Adenocarcinoma

Disease Ontology : ¹² An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary : Clear Cell Adenocarcinoma, also known as mesonephroma, is related to urethra clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Developmental Biology and Endometrial cancer. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, ovary and colon, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Wikipedia : ⁷⁶ Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Sources

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)

#	Related Disease	Score	Top Affiliating Genes
1	urethra clear cell adenocarcinoma	33.9	AMACR KLK3 SMAD4
2	ovarian clear cell adenocarcinoma	33.3	ARID1A HNF1B SMAD3
3	urethral diverticulum	30.4	AMACR KLK3 KRT7
4	endodermal sinus tumor	30.1	KLK3 KRT7 MUC16
5	vulva adenocarcinoma	29.9	KRT20 KRT7
6	transitional cell carcinoma	29.6	KRT20 KRT7 TP53
7	clear cell adenofibroma	29.5	ARID1A KRT7
8	nephrogenic adenoma	29.2	AMACR KLK3 KRT7 PAX2
9	ovarian cancer 1	29.0	ARID1A HNF1B KRT7 TP53
10	renal cell carcinoma, nonpapillary	27.2	AMACR HNF1B KRT20 KRT7 PAX2 PTHLH
11	clear cell adenocarcinoma of the ovary	12.3
12	cervical clear cell adenocarcinoma	12.3
13	endometrial clear cell adenocarcinoma	12.3
14	fallopian tube clear cell adenocarcinoma	12.2
15	bladder clear cell adenocarcinoma	12.1
16	uterine ligament clear cell adenocarcinoma	12.1
17	ampulla of vater clear cell adenocarcinoma	12.1
18	bile duct clear cell adenocarcinoma	12.1
19	bladder tubulo-cystic clear cell adenocarcinoma	12.1
20	bladder papillary clear cell adenocarcinoma	12.1
21	bladder diffuse clear cell adenocarcinoma	12.0
22	diethylstilbestrol syndrome	11.3
23	wolffian duct adenoma	11.1
24	multilocular cystic renal neoplasm of low malignant potential	11.1
25	adenocarcinoma	11.0
26	submandibular gland cancer	10.8	KLK3 TP53
27	atrophy of prostate	10.8	KLK3 TP53
28	mutyh-associated polyposis	10.7	SMAD4 TP53
29	penile disease	10.6	SMAD2 SMAD3
30	malignant spiradenoma	10.5	KRT7 TP53
31	pleomorphic adenoma carcinoma	10.5	PTHLH TP53
32	oligomeganephronia	10.5	HNF1B PAX2
33	female reproductive endometrioid cancer	10.5	KRT7 TP53
34	seminal vesicle tumor	10.5	KLK3 KRT7
35	adenomatoid tumor	10.5	KRT7 MUC16
36	bladder carcinoma in situ	10.5	KRT7 TP53
37	rete testis adenocarcinoma	10.5	KLK3 KRT20
38	breast squamous cell carcinoma	10.5	PTHLH TP53
39	vaginitis	10.5
40	endometriosis	10.5
41	urinary tract obstruction	10.4	KLK3 SMAD2 SMAD3
42	nasal cavity adenocarcinoma	10.4	KRT7 TP53
43	spiradenoma	10.4	KRT7 TP53
44	bladder papillary transitional cell neoplasm	10.4	KRT20 TP53
45	urinary tract papillary transitional cell benign neoplasm	10.4	KRT20 TP53
46	nephrogenic systemic fibrosis	10.4	SMAD2 SMAD3 SMAD4
47	villous adenoma	10.4	KLK3 KRT20
48	esophagus adenocarcinoma	10.4	SMAD4 TP53
49	pancreas adenocarcinoma	10.4	MUC16 SMAD4 TP53
50	cystic basal cell carcinoma	10.4	KRT20 KRT7

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:

Sources

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.02	SMAD4 PTHLH AMACR SMAD2 ARID1A SMAD3
2	endocrine/exocrine gland	MP:0005379	10.01	SMAD4 PAX2 PTHLH TP53 SMAD2 ARID1A
3	embryo	MP:0005380	9.98	SMAD4 PAX2 TP53 SMAD2 ARID1A SMAD3
4	craniofacial	MP:0005382	9.93	SMAD4 PTHLH TP53 SMAD2 ARID1A SMAD3
5	liver/biliary system	MP:0005370	9.8	SMAD4 AMACR SMAD2 SMAD3 HNF1B TP53
6	renal/urinary system	MP:0005367	9.7	PAX2 PTHLH TP53 SMAD3 HNF1B KRT7
7	neoplasm	MP:0002006	9.65	SMAD4 SMAD2 ARID1A SMAD3 TP53
8	reproductive system	MP:0005389	9.5	PAX2 SMAD4 PTHLH SMAD2 ARID1A SMAD3
9	vision/eye	MP:0005391	9.1	PAX2 PTHLH SMAD2 ARID1A SMAD3 TP53

Sources

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Doxorubicin

Approved, Investigational

Phase 3,Phase 2,Phase 1

23214-92-8

31703

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 498142 38904

Gemcitabine

Approved

Phase 3,Phase 2

95058-81-4

60750

Lenograstim

Approved, Investigational

Phase 3,Phase 1

135968-09-1

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

84093 441203 2767

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Docetaxel

Approved, Investigational

Phase 3,Phase 2

114977-28-5

148124

Bevacizumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

216974-75-3

Epirubicin

Approved

Phase 3

56420-45-2

41867

Metformin

Approved

Phase 2, Phase 3

657-24-9

14219 4091

Topotecan

Approved, Investigational

Phase 2, Phase 3

119413-54-6, 123948-87-8

60700

Olaparib

Approved

Phase 3,Phase 2

763113-22-0

23725625

Glutamic Acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Doxil

Approved June 1999

Phase 3,Phase 2,Phase 1

31703

Cediranib

Investigational

Phase 3,Phase 2

288383-20-0

9933475

Maleic acid

Experimental

Phase 3,Phase 2

110-16-7

444266

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Angiogenesis Modulating Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Adjuvants, Immunologic

Phase 3,Phase 1

Mitogens

Phase 3,Phase 2,Phase 1

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Endothelial Growth Factors

Phase 3,Phase 2,Phase 1

Immunoglobulin G

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Anti-Infective Agents

Phase 3,Phase 2,Phase 1

Protein Kinase Inhibitors

Phase 3,Phase 2,Phase 1

Antiviral Agents

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

topoisomerase I inhibitors

Phase 2, Phase 3

Micronutrients

Phase 3,Not Applicable

Trace Elements

Phase 3,Not Applicable

Hypoglycemic Agents

Phase 2, Phase 3

Poly(ADP-ribose) Polymerase Inhibitors

Phase 3,Phase 2,Phase 1

Carotenoids

Phase 3

taxane

Phase 3,Not Applicable

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Vinblastine

Approved

Phase 2

865-21-4

13342 241903

Sunitinib

Approved, Investigational

Phase 2,Not Applicable

341031-54-7, 557795-19-4

5329102

Dasatinib

Approved, Investigational

Phase 2,Phase 1

302962-49-8

3062316

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Miconazole

Approved, Investigational, Vet_approved

Phase 2,Phase 1

22916-47-8

4189

Interventional clinical trials:

(show top 50) (show all 98)

#	Name	Status	NCT ID	Phase	Drugs
1	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3	Carboplatin;Paclitaxel
2	Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer	Completed	NCT00003749	Phase 3
3	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4	Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer	Completed	NCT00005583	Phase 3	cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
5	Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery	Completed	NCT00002807	Phase 3
6	Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer	Completed	NCT00002493	Phase 3	cisplatin;doxorubicin hydrochloride
7	Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer	Completed	NCT00006027	Phase 3	cisplatin;paclitaxel
8	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT02839707	Phase 2, Phase 3	Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
9	Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT02446600	Phase 3	Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
10	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting	NCT00719303	Phase 3
11	Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol	Recruiting	NCT02501954	Phase 3	Cisplatin;Carboplatin;Paclitaxel
12	Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer	Recruiting	NCT03422198	Phase 3
13	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	NCT00565851	Phase 3	Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
14	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer	Active, not recruiting	NCT00108745	Phase 3	Paclitaxel;Paclitaxel Poliglumex
15	Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
16	Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer	Active, not recruiting	NCT00942357	Phase 3	Carboplatin;Cisplatin;Paclitaxel
17	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer	Active, not recruiting	NCT00807768	Phase 3	Carboplatin;Paclitaxel
18	Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer	Active, not recruiting	NCT00411138	Phase 3	cisplatin;carboplatin;Paclitaxel
19	Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer	Active, not recruiting	NCT01672892	Phase 3
20	Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Suspended	NCT02502266	Phase 2, Phase 3	Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
21	Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma	Unknown status	NCT01824615	Phase 2	Sunitinib
22	Immunochemotherapy for Metastatic Renal Cell Carcinoma	Unknown status	NCT00226798	Phase 2	Capecitabine (Xeloda)
23	Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer	Unknown status	NCT01100359	Phase 2	carboplatin;liposome-encapsulated doxorubicin citrate
24	A Study of ENMD-2076 in Ovarian Clear Cell Cancers	Completed	NCT01914510	Phase 2	ENMD-2076
25	AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib	Completed	NCT00467025	Phase 2	AMG 386;Sorafenib;AMG 386 placebo IV
26	Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney	Completed	NCT00853021	Phase 2
27	Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer	Completed	NCT01196429	Phase 2	Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
28	Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer	Completed	NCT00719264	Phase 2	RAD001(everolimus);interferon alfa-2a;bevacizumab
29	LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	Completed	NCT00550277	Phase 2	LBH589
30	Sunitinib in Metastatic Renal Cancer	Completed	NCT01034878	Phase 2	Sunitinib
31	Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01011933	Phase 2	Selumetinib
32	Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00820898	Phase 2	Gemcitabine Hydrochloride
33	High-dose Bevacizumab in Advanced Renal Carcinoma Patients	Completed	NCT00455975	Phase 2	Bevacizumab
34	Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer	Completed	NCT00002562	Phase 2	paclitaxel
35	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
36	Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01132820	Phase 2	Cediranib Maleate
37	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01642082	Phase 2
38	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT01225887	Phase 2	Nintedanib
39	Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00888173	Phase 2	Brivanib Alaninate
40	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer	Completed	NCT01210222	Phase 2
41	Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
42	Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer	Completed	NCT00025467	Phase 2	thalidomide
43	S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer	Completed	NCT00003127	Phase 2	amifostine trihydrate;carboplatin;paclitaxel
44	Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer	Completed	NCT00072176	Phase 2	temsirolimus
45	Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer	Completed	NCT00770185	Phase 2	ridaforolimus
46	Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer	Completed	NCT00113373	Phase 2	lapatinib ditosylate
47	Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium	Recruiting	NCT02866370	Phase 2	Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
48	A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas	Recruiting	NCT03405454	Phase 2	durvalumab;standard chemotherapy
49	BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas	Recruiting	NCT03355976	Phase 2	Nivolumab;Ipilimumab
50	Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.	Recruiting	NCT03066427	Phase 2	Sunitinib

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Sources

Genetic Tests for Clear Cell Adenocarcinoma

Sources

Anatomical Context for Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Clear Cell Adenocarcinoma:

⁴¹

Cervix, Ovary, Colon, Kidney, Lung, Lymph Node, Prostate

Sources

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 423)

#	Title	Authors	Year
1	Ovarian Clear Cell Adenofibroma of Low Malignant Potential Developing Into Clear Cell Adenocarcinoma. ( 29551085 )	Yin Z....Heller D.	2018
2	Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. ( 29979406 )	Zhao L.J....He Y.	2018
3	Clear Cell Adenocarcinoma Arising from Endometriosis in the Groin: Wide Resection and Reconstruction with a Fascia Lata Tensor Muscle Skin Flap. ( 29805826 )	Yoshida S....Kobayashi H.	2018
4	Unusual Features of Clear Cell Adenocarcinoma of the Female Urethra: A Case Report and Literature Review. ( 29977425 )	Zeng J....Lai H.	2018
5	Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. ( 29933751 )	Chao W.T....Wang P.H.	2018
6	Clear cell adenocarcinoma of female urethra: A case report. ( 29888186 )	Hartman K....Garg T.	2018
7	Clear cell adenocarcinoma of the urethra with inguinal lymph node metastases: A rare case report and review of literature. ( 29516944 )	Mallya V....Gayathri J.	2018
8	Follow-up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. ( 29719188 )	Huo D....Herbst A.L.	2018
9	Cervical clear cell adenocarcinoma with an exceptionally low proliferation index: Report of a case. ( 29326971 )	Dandulakis M.G....Hagemann I.S.	2018
10	Clear Cell Adenocarcinoma of the Urethra in Women: Distinctive MRI Findings for Differentiation From Nonadenocarcinoma and Non-Clear Cell Adenocarcinoma of the Urethra. ( 28140610 )	Kim T.H....Kim S.H.	2017
11	Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up. ( 28689666 )	Huo D....Herbst A.L.	2017
12	Clear cell adenocarcinoma of the cervix in second generation young women who are without maternal exposure to diethylstilbestrol: A case report. ( 28275694 )	Tantitamit T....Rangsiratanakul L.	2017
13	Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. ( 29184869 )	Nam G....Kim Y.H.	2017
14	Clear cell adenocarcinoma of cervix in 1-year-old girl without in utero exposure to diethylstilbestrol: an uncommon tumour at an uncommon age and site. ( 28302659 )	Arora A....Husain N.	2017
15	Clear Cell Adenocarcinoma of Female Urethra. ( 28892907 )	Rane S.R....Vishwasrao S.	2017
16	The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )	Sadahira T....Nasu Y.	2017
17	Clear Cell Adenocarcinoma of the Female Urethra, Mimicking Cystocele. ( 28280687 )	Ayari Y....Chebil M.	2017
18	Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )	Miller E.M....Frimer M.	2016
19	A clear cell adenocarcinoma of the gallbladder with hepatoid differentiation: case report and review of literature. ( 27703378 )	Zhang C....Zhao L.	2016
20	Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. ( 27699033 )	Kato M....Furuya K.	2016
21	Clear Cell Adenocarcinoma of the Female Urethra: Four Case Presentations of a Clinical and Pathological Entity Requiring Radical Surgery. ( 26807736 )	Liedberg F....Johansson M.E.	2016
22	Clear Cell Adenocarcinoma of the Lung Mimicking Clear Cell Renal Cell Carcinoma. ( 29772138 )	Wiznia D.H....Leviter J.	2016
23	Clear cell adenocarcinoma of the cervix in a ten-year-old girl without prenatal diethylstilbestrol exposure. ( 27549741 )	Andi Asri A.A....A Latiff L.	2016
24	Clear cell adenocarcinoma arising from adenomyotic cyst: A case report and literature review. ( 26530432 )	Baba A....Miyauchi J.	2015
25	Combined benign Brenner tumor and clear cell adenocarcinoma of the ovary. ( 26150073 )	Matsumoto H....Kato S.	2015
26	Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. ( 26397155 )	Umezaki Y....Yasuhi I.	2015
27	Primary Fallopian Tube Clear Cell Adenocarcinoma in Pregnancy: Case Presentation and Review of the Literature. ( 26090245 )	Malak M....Klam S.	2015
28	Successful radiotherapy for repeated recurrent uterine clear cell adenocarcinoma. ( 26310385 )	Iwashita A....Nakazawa M.	2015
29	High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra. ( 26207115 )	Lewis S....Mahantshetty U.	2015
30	Clear cell adenocarcinoma of the urethra: review of the literature. ( 25685552 )	Venyo A.K.	2015
31	A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. ( 25642923 )	Loizzi V....Selvaggi L.	2015
32	Late recurrence in a case of vaginal clear cell adenocarcinoma unrelated to transplacental diethylstilbestrol exposure. ( 26905123 )	Khan K....Bandyopadhyay A.	2015
33	Clear Cell Adenocarcinoma Arising from Adenofibroma in a Patient with Endometriosis of the Ovary. ( 26498012 )	Cho I....Lim S.C.	2015
34	Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )	Okamoto A....Urashima M.	2015
35	Clear cell adenocarcinoma of the bladder with intravesical cervical invasion. ( 26109625 )	Marchalik D....Venkatesan K.	2015
36	Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )	Matsuo Y....Katabuchi H.	2014
37	Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. ( 25083560 )	Kimura A....Hirano H.	2014
38	Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )	Ikeda Y....Fujii T.	2014
39	Primary non-clear-cell adenocarcinoma of the vagina in a diethylstilbestrol exposed woman. ( 24690973 )	Patel S.A....Sunde J.	2014
40	Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )	Morimoto A....Fujiwara K.	2014
41	Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. ( 25010038 )	Suzuki K....Okamoto A.	2014
42	Therapy of a clear cell adenocarcinoma of unknown primary arising in the abdominal wall after cesarean section and after hysterectomy. ( 25301100 )	Aust S....Langer M.	2014
43	A case of clear cell adenocarcinoma arising from endometriosis of the rectum treated by laparoscopic surgery. ( 25460452 )	Okazawa Y....Sakamoto K.	2014
44	Clear cell adenocarcinoma present exclusively within endometrial polyp: report of two cases. ( 24817975 )	Ishida M....Okabe H.	2014
45	Clear Cell Adenocarcinoma of the Urethra: 18F-FDG PET/CT Imaging. ( 25140553 )	Nguyen B.D.	2014
46	Primary clear cell adenocarcinoma of the peritoneum presents as Sister Mary Joseph's nodule: a case report and literature review. ( 25556287 )	Zhang C.J....Da J.	2014
47	Primary Urethral Clear-Cell Adenocarcinoma: Comprehensive Analysis by Surgical Pathology, Cytopathology, and Next-Generation Sequencing. ( 24389164 )	Mehra R....Chinnaiyan A.M.	2014
48	Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. ( 24815386 )	Goto Y....Mikami M.	2014
49	Cervical clear cell adenocarcinoma infected with human papillomavirus type 18 in an adolescent. ( 23849091 )	Guo Y....Liu H.	2014
50	Clear Cell Adenocarcinoma of the Prostate: A Rare Oncologic Entity in a 42-Year-Old African American Man. ( 25217452 )	Klaassen Z....Moses K.A.	2014

Sources

Genes for Clear Cell Adenocarcinoma

Genes related to Clear Cell Adenocarcinoma (0 elite genes):

(show all 13)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	KLK3	Kallikrein Related Peptidase 3	Protein Coding	26.3	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	7536368 9865832 7645457 (more) 11251541 7512941
2	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	25.46	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9234924 17713092
3	SMAD4	SMAD Family Member 4	Protein Coding	25.23	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16820918
4	SMAD3	SMAD Family Member 3	Protein Coding	25	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16820918
5	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	23.59	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10637074
6	HNF1B	HNF1 Homeobox B	Protein Coding	23.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	KRT7	Keratin 7	Protein Coding	22.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	KRT20	Keratin 20	Protein Coding	22.36	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	PAX2	Paired Box 2	Protein Coding	21.94	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	21.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	SMAD2	SMAD Family Member 2	Protein Coding	21.72	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16820918
12	AMACR	Alpha-Methylacyl-CoA Racemase	Protein Coding	21.62	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	TP53	Tumor Protein P53	Protein Coding	21.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

⁷

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	218693	7	116312458	116438439	Amplification	MET	Clear cell adenocarcinoma
2	266962	Y	174481503	174538309	Duplication	AZF	Clear cell adenocarcinoma

Sources

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Sources

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 45)

#	Super pathways	Score	Top Affiliating Genes
1	Developmental Biology ⁶⁶ Show member pathways Axon guidance ⁶⁶	13.38	HNF1B KRT20 KRT7 SMAD2 SMAD3 SMAD4
2	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.73	KLK3 SMAD2 SMAD3 SMAD4 TP53
3	Pathways in cancer ³⁷	12.69	KLK3 SMAD2 SMAD3 SMAD4 TP53
4	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.61	ARID1A SMAD2 SMAD3 SMAD4 TP53
5	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.45	SMAD2 SMAD3 SMAD4 TP53
6	Human Embryonic Stem Cell Pluripotency ⁶⁴ Show member pathways Factors Promoting Cardiogenesis in Vertebrates ⁶⁴	12.38	HNF1B SMAD2 SMAD3 SMAD4
7	HTLV-I infection ³⁷	12.32	SMAD2 SMAD3 SMAD4 TP53
8	Cell cycle ¹ ³⁷	12.24	SMAD2 SMAD3 SMAD4 TP53
9	DNA Damage/Telomere Stress Induced Senescence ⁶⁶ Show member pathways Formation of Senescence-Associated Heterochromatin Foci (SAHF) ⁶⁶ Packaging Of Telomere Ends ⁶⁶ Signal transduction Activin A signaling regulation ²²	12.22	SMAD2 SMAD3 SMAD4 TP53
10	Mesodermal Commitment Pathway ¹ Show member pathways Endoderm Differentiation ¹	12.14	HNF1B PTHLH SMAD2 SMAD3 SMAD4
11	Cell cycle Role of SCF complex in cell cycle regulation ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Regulation of G1/S transition (part 1) ²² Immune response MIF-JAB1 signaling ²²	12.12	SMAD2 SMAD3 SMAD4
12	Cellular senescence (KEGG) ³⁷	12.07	SMAD2 SMAD3 TP53
13	Wnt / Hedgehog / Notch ⁴	12.06	PAX2 SMAD2 SMAD3 SMAD4
14	Hippo signaling pathway ³⁷	12.05	SMAD2 SMAD3 SMAD4
15	Integrated Breast Cancer Pathway ¹	12.05	SMAD2 SMAD4 TP53
16	Signaling pathways regulating pluripotency of stem cells ³⁷	12	SMAD2 SMAD3 SMAD4
17	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	11.99	SMAD2 SMAD3 SMAD4
18	Apelin signaling pathway ³⁷	11.99	SMAD2 SMAD3 SMAD4
19	Colorectal Cancer Metastasis ⁶⁴	11.95	SMAD2 SMAD3 SMAD4 TP53
20	DNA Damage Response (only ATM dependent) ¹	11.91	SMAD3 SMAD4 TP53
21	Senescence and Autophagy in Cancer ¹	11.87	SMAD3 SMAD4 TP53
22	SMAD Signaling Network ⁶⁴	11.84	SMAD2 SMAD3 SMAD4 TP53
23	AGE-RAGE signaling pathway in diabetic complications ³⁷	11.83	SMAD2 SMAD3 SMAD4
24	TGF-beta Signaling Pathway (WikiPathways) ¹	11.83	SMAD2 SMAD3 SMAD4 TP53
25	TGF-beta Signaling Pathways ⁶⁵	11.81	SMAD2 SMAD3 SMAD4
26	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.8	SMAD2 SMAD3 SMAD4
27	Androgen receptor signaling pathway ¹	11.78	KLK3 SMAD3 SMAD4
28	TGF-beta signaling pathway (KEGG) ³⁷	11.74	SMAD2 SMAD3 SMAD4
29	Validated targets of C-MYC transcriptional activation ¹	11.72	SMAD3 SMAD4 TP53
30	Loss of Function of SMAD2/3 in Cancer ⁶⁶ Show member pathways BMP Signalling Pathway ¹ Canonical and Non-Canonical TGF-B signaling ¹ Loss of Function of SMAD4 in Cancer ⁶⁶ Loss of Function of TGFBR1 in Cancer ⁶⁶ Loss of Function of TGFBR2 in Cancer ⁶⁶ SMAD2/3 MH2 Domain Mutants in Cancer ⁶⁶ SMAD2/3 Phosphorylation Motif Mutants in Cancer ⁶⁶ SMAD4 MH2 Domain Mutants in Cancer ⁶⁶ TGFBR1 KD Mutants in Cancer ⁶⁶ TGFBR1 LBD Mutants in Cancer ⁶⁶ TGFBR2 Kinase Domain Mutants in Cancer ⁶⁶ TGFBR2 MSI Frameshift Mutants in Cancer ⁶⁶	11.69	SMAD2 SMAD3 SMAD4
31	Regulation of nuclear SMAD2/3 signaling ¹	11.69	SMAD2 SMAD3 SMAD4
32	Adherens junction ³⁷	11.64	SMAD2 SMAD3 SMAD4
33	Development_TGF-beta receptor signaling ²²	11.64	SMAD2 SMAD3 SMAD4
34	TGF-beta receptor signaling activates SMADs ⁶⁶ Show member pathways Downregulation of TGF-beta receptor signaling ⁶⁶ Signaling by TGF-beta Receptor Complex in Cancer ⁶⁶	11.62	SMAD2 SMAD3 SMAD4
35	TGF-beta Receptor Signaling (WikiPathways) ¹	11.5	SMAD2 SMAD3 SMAD4
36	Hepatitis C and Hepatocellular Carcinoma ¹	11.42	SMAD3 SMAD4 TP53
37	TGF-beta receptor signaling (Pathway Interaction Database) ¹	11.41	SMAD2 SMAD3 SMAD4
38	Signaling by NODAL ⁶⁶ Show member pathways Antagonism of Activin by Follistatin ⁶⁶ Regulation of signaling by NODAL ⁶⁶ Signaling by Activin ⁶⁶	11.39	SMAD2 SMAD3 SMAD4
39	Integrated Cancer Pathway ¹	11.32	SMAD2 SMAD3 TP53
40	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁴ Show member pathways TOB in T-Cell Signaling ⁶⁴	11.19	SMAD2 SMAD3 SMAD4
41	Extracellular vesicle-mediated signaling in recipient cells ¹	11.02	SMAD2 SMAD3 SMAD4
42	NTHi-Induced Signaling ⁶⁴	11	SMAD3 SMAD4
43	Hypothesized Pathways in Pathogenesis of Cardiovascular Disease ¹	10.73	SMAD2 SMAD3 SMAD4
44	Regulation of cytoplasmic and nuclear SMAD2/3 signaling ¹	10.41	SMAD2 SMAD3 SMAD4
45	TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition ¹	10.05	SMAD2 SMAD3 SMAD4

Sources

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription factor complex	GO:0005667	9.62	HNF1B SMAD2 SMAD3 SMAD4
2	nuclear chromatin	GO:0000790	9.35	ARID1A SMAD2 SMAD3 SMAD4 TP53
3	activin responsive factor complex	GO:0032444	9.26	SMAD2 SMAD4
4	heteromeric SMAD protein complex	GO:0071144	9.16	SMAD2 SMAD3
5	SMAD protein complex	GO:0071141	8.8	SMAD2 SMAD3 SMAD4

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 33)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of transcription by RNA polymerase II	GO:0000122	9.97	ARID1A HNF1B SMAD2 SMAD3 SMAD4 TP53
2	positive regulation of gene expression	GO:0010628	9.94	HNF1B SMAD2 SMAD3 TP53
3	negative regulation of cell proliferation	GO:0008285	9.92	PTHLH SMAD2 SMAD3 SMAD4 TP53
4	protein deubiquitination	GO:0016579	9.89	SMAD2 SMAD3 SMAD4 TP53
5	negative regulation of cell growth	GO:0030308	9.8	SMAD3 SMAD4 TP53
6	positive regulation of transcription, DNA-templated	GO:0045893	9.8	ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4
7	anterior/posterior pattern specification	GO:0009952	9.79	HNF1B SMAD2 SMAD4
8	transforming growth factor beta receptor signaling pathway	GO:0007179	9.79	SMAD2 SMAD3 SMAD4
9	SMAD protein signal transduction	GO:0060395	9.72	SMAD2 SMAD3 SMAD4
10	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.69	SMAD2 SMAD3 SMAD4
11	embryonic pattern specification	GO:0009880	9.66	SMAD2 SMAD3
12	positive regulation of pri-miRNA transcription by RNA polymerase II	GO:1902895	9.65	SMAD3 TP53
13	signal transduction involved in regulation of gene expression	GO:0023019	9.65	SMAD2 SMAD3
14	osteoblast development	GO:0002076	9.64	PTHLH SMAD3
15	activin receptor signaling pathway	GO:0032924	9.63	SMAD2 SMAD3
16	secondary palate development	GO:0062009	9.62	SMAD2 SMAD4
17	nodal signaling pathway	GO:0038092	9.61	SMAD2 SMAD3
18	primary miRNA processing	GO:0031053	9.6	SMAD2 SMAD3
19	pericardium development	GO:0060039	9.58	SMAD2 SMAD3
20	embryonic foregut morphogenesis	GO:0048617	9.58	SMAD2 SMAD3
21	developmental growth	GO:0048589	9.58	SMAD2 SMAD3 SMAD4
22	pronephros development	GO:0048793	9.56	HNF1B PAX2
23	regulation of transforming growth factor beta2 production	GO:0032909	9.54	SMAD3 SMAD4
24	regulation of transforming growth factor beta receptor signaling pathway	GO:0017015	9.54	SMAD2 SMAD3 SMAD4
25	SMAD protein complex assembly	GO:0007183	9.5	SMAD2 SMAD3 SMAD4
26	negative regulation of mesenchymal cell apoptotic process involved in metanephros development	GO:1900212	9.48	HNF1B PAX2
27	nephric duct formation	GO:0072179	9.46	HNF1B PAX2
28	gastrulation	GO:0007369	9.46	ARID1A SMAD2 SMAD3 SMAD4
29	paraxial mesoderm morphogenesis	GO:0048340	9.43	SMAD2 SMAD3
30	endoderm development	GO:0007492	9.26	HNF1B SMAD2 SMAD3 SMAD4
31	regulation of binding	GO:0051098	8.8	SMAD2 SMAD3 SMAD4
32	transcription, DNA-templated	GO:0006351	10.2	ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4
33	positive regulation of transcription by RNA polymerase II	GO:0045944	10.04	HNF1B PAX2 SMAD2 SMAD3 SMAD4 TP53

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	RNA polymerase II transcription factor activity, sequence-specific DNA binding	GO:0000981	9.87	ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4
2	chromatin binding	GO:0003682	9.84	SMAD2 SMAD3 SMAD4 TP53
3	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	9.81	SMAD2 SMAD3 SMAD4 TP53
4	transcription factor binding	GO:0008134	9.78	PAX2 SMAD2 SMAD3 TP53
5	protein heterodimerization activity	GO:0046982	9.77	HNF1B SMAD2 SMAD3 SMAD4 TP53
6	transcription factor activity, transcription factor binding	GO:0000989	9.55	SMAD3 SMAD4
7	enhancer binding	GO:0035326	9.49	SMAD2 SMAD3
8	co-SMAD binding	GO:0070410	9.46	SMAD2 SMAD3
9	I-SMAD binding	GO:0070411	9.43	SMAD2 SMAD4
10	primary miRNA binding	GO:0070878	9.4	SMAD2 SMAD3
11	transcription regulatory region DNA binding	GO:0044212	9.35	HNF1B PAX2 SMAD3 SMAD4 TP53
12	R-SMAD binding	GO:0070412	9.33	SMAD2 SMAD3 SMAD4
13	transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity	GO:0030618	9.26	SMAD2 SMAD3
14	proximal promoter sequence-specific DNA binding	GO:0000987	8.92	HNF1B PAX2 SMAD3 SMAD4
15	DNA binding	GO:0003677	10.07	ARID1A HNF1B PAX2 SMAD2 SMAD3 SMAD4

Sources

Sources for Clear Cell Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia